Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 408-210-8 | CAS number: 124605-82-9 C.I. DIRECT BLUE 301; DIRECT BLUE 301
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
28 day oral repeated dose toxicity: NOAEL = 100 mg/kg bw ; OECD 407 Guideline Study
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 100 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Additional information
In a subacute toxicity study according to OECD guideline 407 and following GLP principles, doses of 0, 20, 100 or 500 mg/kg body weight/day of test article were administered daily via gavage to rats of both sexes for 28 days (RCC, 1990). At the dose level of 500 mg/kg body weight/day an increase in organ weights (liver, kidney and adrenals) and slight changes in hematology (slight increase in the reticulocyte count and slight polychromatophilia for females) and clinical chemistry parameters (slightly increased urea, bilirubin, triglyceride, phospholipid and calcium concentrations, slightly decreased sodium concentrations) were seen. Absolute liver, kidney and adrenal weights and/or their ratios to body weight or brain weight were statistically significantly higher than the corresponding controls in both sexes of group 4 (500 mg/kg). Relative spleen weights were statistically significantly higher than controls in males of group 4. Except for the liver to body weight ratios of females of group 4, all of these findings had returned to normal in recovery individuals after an additional two weeks of abstinence from the test article. Many male and female rats of group 4 (500 mg/kg) and one group 2 (20 mg/kg) male animal were found to have discoloration of the gastro-intestinal tract, but there were no concomitant histological findings. The livers from Group 4, main test and recovery animals, showed a slight increase in periportal mononuclear cell infiltration. There was an increase in the number of animals showing moderate hyaline droplet degeneration in the male main test kidneys in groups 3 (100 mg/kg) and 4, which was not apparent in the recovery animals.
The liver was identified as a potential target organ because of the increases in liver weight, the severity of periportal mononuclear cell infiltration and in reticulocyte counts; the kidney because of the increases in kidney weight and in the number of males showing moderate hyaline droplet degeneration in the kidneys. The changes in the blood biochemistry parameters listed above were considered to be of metabolic nature possibly due to changes in the liver and kidneys. A further potential target organ may be the spleen, because of the increases in spleen weight in high dose males and the increases in reticulocytes in high dose females. Except for the histopathology findings in the liver and the liver to body weight ratio in females, the above findings had returned to normal in recovery individuals of group 4 (500 mg/kg) by the end of the treatment-free 14-day recovery period. Therefore, the "no-adverse effect level" was set at 100 mg/kg, despite the finding of moderate hyaline degeneration in the kidneys of males of group 3 (100 mg/kg) at termination of treatment.
Repeated dose toxicity: via oral route - systemic effects (target organ) digestive: liver; urogenital: kidneys
Justification for classification or non-classification
A subacute 28 day oral toxicity study resulted in a NOAEL of 100 mg/kg bw/day and a LOAEL of 500 mg/kg bw/d.
Based on the nature of effects and the lowest effect level obtained in this OECD guideline study, no classification according to EU and GHS criteria is necessary.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.